Biora Therapeutics Inc - Asset Resilience Ratio
Biora Therapeutics Inc (BIOR) has an Asset Resilience Ratio of 17.35% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BIOR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2019)
This chart shows how Biora Therapeutics Inc's Asset Resilience Ratio has changed over time. See Biora Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Biora Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Biora Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $20.20 Million | 17.35% |
| Total Liquid Assets | $20.20 Million | 17.35% |
Asset Resilience Insights
- Good Liquidity Position: Biora Therapeutics Inc maintains a healthy 17.35% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Biora Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Biora Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for Biora Therapeutics Inc (2018–2019)
The table below shows the annual Asset Resilience Ratio data for Biora Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $101.73 Million | -- |
| 2018-12-31 | 17.35% | $20.20 Million | $116.40 Million | -- |
About Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more